Description: Theseus is a biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development and commercialization of transformative targeted therapies. Theseus is developing next-generation tyrosine kinase inhibitors (TKIs): "pan-variant" targeted therapies that address all major drug resistance mutations. Theseus' lead product candidate, THE-630, is a pan-variant KIT inhibitor for the treatment of patients with advanced gastrointestinal stromal tumors (GIST), whose cancer has developed resistance to earlier lines of kinase inhibitor therapy. Theseus is also developing a fourth-generation, selective epidermal growth factor receptor (EGFR) inhibitor for C797S-mediated resistance to first- or later-line osimertinib treatment in patients with non-small cell lung cancer (NSCLC).
Home Page: theseusrx.com
THRX Technical Analysis
245 Main Street
Cambridge,
MA
02142
United States
Phone:
857 400 9491
Officers
| Name | Title |
|---|---|
| Dr. Iain D. Dukes D.Phil., DPHIL, M.A. | Co-Founder & Chairman |
| Dr. Timothy P. Clackson Ph.D. | CEO, Pres & Director |
| Dr. William C. Shakespeare Ph.D. | Co-Founder and Pres of R&D |
| Mr. Bradford D. Dahms | Chief Financial officer |
| Dr. Victor M. Rivera Ph.D. | Co-Founder, Sr. VP & Chief Scientific Officer |
| Mr. Wei-Sheng Huang Ph.D. | Co-Founder & VP of Chemistry |
| Mr. Benjamin D. Enerson | VP of Legal Affairs |
| Dr. David P. Kerstein M.D. | Chief Medical Officer |
| Dr. Nachu Narasimhan Ph.D. | Sr. VP of Drug Metabolism & Preclinical Safety |
| Mr. Len Rozamus | Sr. VP of Technical Operations |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 1.0396 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2021-10-07 |
| Fiscal Year End: | December |
| Full Time Employees: | 26 |